[Phalus sarcomatoid carcinoma, a case study]. / Carcinome a cellules fusiformes (sarcomatoide) du penis. a propos d'un cas.

The sarcomatoid carcinoma is a rare histological form, high grade malignancy, aggressive and dark prognosis. We report a (01) case in a young adult of 32 years. The aim of this work is to present, through a review of the literature, the epidemiological and morphological characteristics of this affection; and also to describe the difficulties that the pathologist may encounter in diagnosis of this condition.

Le carcinome sarcomatoide en est une variante rare du carcinome épidermoïde, de haut grade de malignité, agressive et de pronostic sombre. Nous rapportons un (01) cas chez un jeune adulte de 32 ans. Le but de ce travail est de présenter à travers une revue de la littérature, les caractères épidémiologique et morphologique de cette affection ; et aussi de décrire les difficultés du diagnostic histopathologique.

Carcinome à cellules fusiformes (sarcomatoide) du pénis. A propos d'un cas

Le carcinome sarcomatoide en est une variante rare du carcinome épidermoïde, de haut grade de malignité, agressive et de pronostic sombre. Nous rapportons un (01)cas chez un jeune adulte de 32 ans. Le but de ce travail est de présenter à travers une revue de la littérature,les caractères épidémiologique et morphologique de cette affection; et aussi de décrire les difficultés du diagnostichistopathologique

Management of Renal Cell Carcinoma-Current Practice in Sub-Saharan Africa.

There is a global variation in the incidence of renal masses with the developed nations having a greater incidence. About 80-90% of renal malignancies are renal cell carcinomas (RCC) which account for 2-4% of all cancers. In Africa and the Middle East, the age-standardized incidence for RCC is 1.8-4.8/100,000 for males and 1.2-2.2/100,000 for females. The management of renal cell cancer is challenging. A multidisciplinary approach is effective for diagnosis, staging, and treatment. Guidelines recommend active surveillance, thermal ablation, partial nephrectomy, radical nephrectomy, cytoreductive nephrectomy and immunotherapy as various modalities for various stages of RCC. However, open radical nephrectomy is most widely adopted as an option for treatment at various stages of the disease in sub-Saharan Africa due to its cost-effectiveness, applicability at various stages, and the reduced cost of follow-up. Nevertheless, most patients in the region present with the disease in the advanced stage and despite surgery the prognosis is poor.

Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline.

The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.

A Review of Localized Prostate Cancer: An African Perspective.

Prostate cancer is the second most common malignancy in males and the sixth leading cause of cancer mortality in men with a relatively higher death rate in men of African descent. In the United States and other parts of Europe, more than 80% of diagnosed prostate cancer is localized, and 80-90% of these men receive some form of treatment. The projected data may not be a direct reflection of the disease in the sub-Saharan region as less than 40% presents with localized disease. Results from prostate cancer screening have shown that most African men in the sub-region have little knowledge of the disease. There are recommended international guidelines for the management of localized prostate cancer, however, a guideline in a local context could be ideal.